PRQR N Stock Overview
A biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ProQR Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.00 |
| 52 Week High | US$27.00 |
| 52 Week Low | US$15.00 |
| Beta | 0.045 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 70.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| PRQR N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 70.3% | 0% | 0% |
Return vs Industry: PRQR N exceeded the MX Biotechs industry which returned -6% over the past year.
Return vs Market: PRQR N exceeded the MX Market which returned 3.7% over the past year.
Price Volatility
| PRQR N volatility | |
|---|---|
| PRQR N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: PRQR N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PRQR N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 130 | Daniel de Boer | www.proqr.com |
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline.
ProQR Therapeutics N.V. Fundamentals Summary
| PRQR N fundamental statistics | |
|---|---|
| Market cap | Mex$3.18b |
| Earnings (TTM) | -Mex$1.29b |
| Revenue (TTM) | Mex$95.32m |
33.4x
P/S Ratio-2.5x
P/E RatioIs PRQR N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRQR N income statement (TTM) | |
|---|---|
| Revenue | €4.80m |
| Cost of Revenue | €0 |
| Gross Profit | €4.80m |
| Other Expenses | €69.91m |
| Earnings | -€65.11m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,355.91% |
| Debt/Equity Ratio | 10.4% |
How did PRQR N perform over the long term?
See historical performance and comparison